Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis

NCT02980705 is registered in ClinicalTrials.gov with Sun Pharmaceutical Industries Limited as lead sponsor.

NCT NCT02980705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02980705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis
Lead sponsor
Sun Pharmaceutical Industries Limited
Phase
Phase 2
Overall status
Terminated
Start date
November 6, 2017
Completion date
September 3, 2019
Enrollment
180 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

active ankylosing spondylitis or non-radiographic axial spondyloarthritis